North Carolina Headlines

DelveInsight’s “Treatment-Resistant Depression Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of the market dynamics, competitive landscape, key growth drivers, emerging therapies, and future opportunities shaping the global Treatment-Resistant Depression industry.

Interested to know which Treatment-Resistant Depression therapies will capture the highest market share? Download the report to understand the latest Treatment-Resistant Depression market trends and forecasts – https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from the Treatment-Resistant Depression Market Report

• The total Treatment-Resistant Depression market size in the 7MM was approximately ~USD 3,100 million in 2022 and is projected to increase significantly during the forecast period (2026–2036).

• Treatment-Resistant Depression typically refers to an inadequate response to at least two antidepressant medications used for a sufficient time at an adequate dose, with up to 50–60% of patients not achieving adequate response following antidepressant treatment.

• Rising prevalence of TRD across the 7MM continues to drive demand for advanced treatment options, supported by increasing diagnosis rates, growing mental health awareness, and limited long-term effectiveness of conventional antidepressants.

• Increasing demand for rapid-acting therapies such as esketamine and psychedelic-based treatments is accelerating innovation in the Treatment-Resistant Depression treatment landscape.

• The expanding pipeline, including COMP360 (COMPASS Pathways), BPL-003 (Beckley Psytech), VLS-01 (AtaiBeckley), and MIJ821 (Novartis), is expected to significantly reshape the competitive landscape.

• In 2022, the US captured the highest Treatment-Resistant Depression market share at 84%, followed by Germany at 5%, out of all 7MM countries.

• As per DelveInsight analysis, there were approximately 6.6 million prevalent cases of TRD across the 7MM in 2025, with this figure projected to rise by 2036.

• SPRAVATO (esketamine) by Johnson & Johnson remains the only FDA-approved nasal spray indicated for Treatment-Resistant Depression.

• Nonpharmacological treatment advances, including ECT, rTMS, VNS, and CBT, continue to evolve and gain acceptance in TRD management.

• Leading Treatment-Resistant Depression companies include Navitor Pharmaceuticals, Supernus Pharmaceuticals, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others.

Gain a competitive edge in the Treatment-Resistant Depression Market by exploring our in-depth analysis @ Treatment-Resistant Depression Market Report – https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Treatment-Resistant Depression Market Overview

The global Treatment-Resistant Depression market is transforming the neuropsychiatric treatment landscape through the emergence of novel rapid-acting pharmacological and nonpharmacological therapeutic approaches. Treatment-Resistant Depression typically refers to an inadequate response to at least two antidepressant medications used for a sufficient time at an adequate dose with adequate affirmation of treatment adherence, with up to 50–60% of patients not achieving adequate response following antidepressant treatment.

Growing TRD prevalence worldwide, combined with increasing demand for durable and effective treatment solutions, continues to fuel market growth. The integration of advanced psychedelic-based therapies, neuromodulation techniques, and biomarker-guided personalized treatment strategies has further expanded the clinical applications across diagnosis, treatment monitoring, and precision psychiatry. Furthermore, the expanding pipeline of innovative therapies is expected to drive substantial reconstitution of the Treatment-Resistant Depression treatment space during the forecast period.

Factors Driving the Growth of the Treatment-Resistant Depression MarketRising Prevalence of Treatment-Resistant Depression

The prevalence of TRD continues to rise across the 7MM due to increasing diagnosis rates, growing mental health awareness, and the limited long-term effectiveness of conventional antidepressants. Many patients fail to achieve adequate symptom control despite multiple lines of therapy, increasing the overall patient burden and demand for advanced treatment options.

Growing Burden of Comorbid Conditions

TRD is frequently associated with psychiatric and physical comorbidities such as anxiety disorders, chronic pain, and fibromyalgia. Patients with these overlapping conditions generally experience greater disease severity, poorer quality of life, and higher healthcare utilization, thereby increasing the need for effective and durable therapies.

Increasing Demand for Rapid-Acting Therapies

Traditional antidepressants often require several weeks to demonstrate therapeutic benefit, while many patients discontinue therapy because of inadequate response or intolerable side effects. This has accelerated demand for rapid-acting therapies such as esketamine and psychedelic-based treatments capable of producing faster antidepressant effects and improving patient adherence.

Expansion of Psychedelic-Based Therapeutic Development

The TRD pipeline is increasingly focused on psychedelic-based therapies, including COMP360, BPL-003, and VLS-01. These therapies are attracting significant clinical and commercial attention because of their potential to provide rapid, durable antidepressant responses in patients who have failed conventional treatment approaches.

Advancements in Nonpharmacological Treatment Approaches

Nonpharmacological interventions such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), and cognitive behavioral therapy (CBT) continue to evolve and gain acceptance in TRD management. Improved accessibility and technological advancements in neuromodulation are supporting broader adoption of these treatment modalities.

Strong Research and Development Activity

The TRD market is witnessing robust R&D investment from biopharmaceutical companies focused on innovative mechanisms of action and next-generation neuropsychiatric therapies. Ongoing clinical trials, regulatory interactions, and breakthrough therapy designations are expected to accelerate future therapy approvals and expand the competitive landscape.

Treatment-Resistant Depression Market Segment Analysis

The Treatment-Resistant Depression treatment market is dominated by pharmacological therapies, including selective serotonin reuptake inhibitors (SSRIs), dual serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), and other antidepressant classes. SPRAVATO (esketamine) and SYMBYAX remain the two FDA-approved drugs specifically for Treatment-Resistant Depression, with SPRAVATO being the only FDA-approved nasal spray indicated for TRD.

Nonpharmacological therapies, including electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), vagus nerve stimulation (VNS), cognitive-behavioral therapy (CBT), and interpersonal therapy (IPT), represent a growing segment. Technological advancements in neuromodulation and increasing accessibility of these interventions are expected to further strengthen segment growth during the forecast period.

Treatment-Resistant Depression Market Regional Analysis

The United States is Expected to Dominate the Overall Treatment-Resistant Depression Market

The United States accounted for the highest Treatment-Resistant Depression market share at approximately 84% in 2022, supported by advanced psychiatric care infrastructure, high healthcare spending, growing mental health awareness, and increasing adoption of innovative treatment options including esketamine. In 2025, an estimated 1.2 million males and 3.4 million females in the US were affected by TRD, with the condition being more prevalent among females, reflecting broader trends in depression diagnoses.

Among the EU4 countries, Germany accounted for 5% of the 7MM market share in 2022, followed by other EU4 nations contributing progressively to overall market revenue. The UK reported around 120,000 male and 290,000 female TRD cases in 2025, with this gender trend expected to rise by 2036, and a market size of approximately ~USD 110 million in 2022.

In Japan, the Treatment-Resistant Depression market size is expected to increase at a CAGR of 2% during the forecast period (2026–2036), with the highest number of TRD cases in 2025 occurring in the 40–49 age group, with more than 90,000 cases.

Treatment-Resistant Depression Key Companies

Treatment-Resistant Depression Companies include:

• Navitor Pharmaceuticals

• Supernus Pharmaceuticals

• Novartis

• Relmada Therapeutics

• Beckley Psytech

• COMPASS Pathways

• Axsome Therapeutics

• Celon Pharma

• And Others.

Download the report to understand which factors are driving Treatment-Resistant Depression Market Trends – https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Latest Highlights from the Treatment-Resistant Depression Market

• In April 2026, COMPASS Pathways announced that the US FDA granted an NDA rolling review request and awarded a Commissioner’s National Priority Voucher (CNPV) for COMP360 (psilocybin) for the treatment of TRD, further accelerating its regulatory pathway toward potential approval.

• In March 2026, Atai Beckley announced that BPL-003 (mebufotenin benzoate nasal spray) demonstrated rapid and durable antidepressant effects in patients with TRD, with the company remaining on track to initiate its Phase III development program in Q2 2026.

• In January 2026, Johnson & Johnson presented new post-hoc Phase III analyses of SPRAVATO (esketamine) at the American College of Neuropsychopharmacology Annual Meeting, highlighting improvements in anhedonia among adults with TRD and reinforcing the therapy’s clinical utility in the treatment landscape.

• COMP360 has received Breakthrough Therapy Designation (BTD) from the US FDA and Innovative Licensing and Access Pathway (ILAP) designation in the UK for Treatment-Resistant Depression.

• Strategic collaborations between biopharmaceutical companies and academic research centers are accelerating clinical development and commercialization of novel TRD therapies.

• Growing awareness among healthcare providers and patients is contributing to earlier intervention and greater adoption of emerging therapies.

Discover key developments and opportunities in the Treatment-Resistant Depression Market @ Treatment-Resistant Depression Market Size – https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Treatment-Resistant Depression Market Outlook

The Treatment-Resistant Depression market is experiencing significant transformation as healthcare systems increasingly embrace innovative pharmacological and nonpharmacological approaches to managing this complex condition. Advances in psychedelic-based therapeutics, neuromodulation technologies, AI-powered diagnostics, and personalized treatment strategies are substantially improving clinical outcomes for TRD patients.

The market is also benefiting from expanding applications in biomarker-guided therapy selection, rapid-acting treatment protocols, and novel mechanisms of action targeting NMDA, serotonin, and glutamate pathways. Growing investments, strategic partnerships, regulatory support including breakthrough therapy designations, and increasing reimbursement frameworks are expected to further accelerate innovation and commercialization.

As precision psychiatry continues to gain momentum, Treatment-Resistant Depression therapies are positioned to become integral components of mental health management, enabling earlier intervention, improved patient outcomes, and more personalized treatment strategies across the US, EU4, UK, and Japan markets.

Scope of the Treatment-Resistant Depression Market Report

Study Period: 2022–2036

Forecast Period: 2026–2036

Geographies Covered: The US, EU4 (Germany, France, Italy, and Spain), UK, Japan

Major Treatment-Resistant Depression Companies: Navitor Pharmaceuticals, Supernus Pharmaceuticals, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others.

Market Segments Covered: Total Market Size, Market Size by Therapies, Market Size by Class, and Geography.

Epidemiology Segmentation: Total Prevalent Cases of Treatment-Resistant Depression in the 7MM, Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in the 7MM.

Competitive Intelligence Analysis: Market trends, competitive landscape, strategic collaborations, regulatory approvals, pipeline developments, and emerging therapies.

Key Focus Areas: Psychedelic-Based Therapies, Rapid-Acting Antidepressants, Neuromodulation, NMDA Receptor Antagonists, Personalized Treatment Strategies, and Nonpharmacological Interventions.

Table of Contents

1. Report Introduction

2. Treatment-Resistant Depression (TRD) Market Overview at a Glance

3. Executive Summary of Treatment-Resistant Depression (TRD)

4. Key Events

5. Disease Background and Overview

6. Treatment

7. Methodology

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Drugs

11. Emerging Drugs

12. Treatment-Resistant Depression (TRD): Seven Major Market Analysis

13. KOL Views

14. SWOT Analysis

15. Unmet Needs

16. Reimbursement and Market Access

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

How DelveInsight’s Treatment-Resistant Depression Market Report Helps CXOs and Business Leaders

• Evaluate the current and future market opportunity across key regions, including the United States, EU4, UK, and Japan, through detailed market forecasts, epidemiology assessments, and growth trend analysis.

• Benchmark leading Treatment-Resistant Depression therapies and diagnostic approaches through comprehensive competitive intelligence, company profiling, product portfolio evaluation, and innovation tracking.

• Identify potential licensing, acquisition, co-development, and strategic partnership opportunities by monitoring emerging market participants, novel therapeutic mechanisms, and recent industry collaborations, mergers, and investments.

• Assess the impact of upcoming regulatory approvals, clinical trial readouts, reimbursement developments, and product launches on market share, pricing strategies, adoption rates, and commercial success.

• Support strategic decision-making with insights into key opinion leader (KOL) perspectives, unmet treatment needs, clinical adoption trends, therapy utilization patterns, patient stratification approaches, and evolving market dynamics within the Treatment-Resistant Depression landscape.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market